Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05616013 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 507
- Enrollment target
NCT05616013 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 507 participants.
The verdict
NCT05616013, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 507 participants
- Enrollment target
Study Summary
A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
Interventions
- OTHER Placebo
- DRUG Semaglutide
- BIOLOGICAL Bimagrumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 507 participants |
| Start Date | 2022-11-16 |
| Est. Completion | 2025-06-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05616013
The ClinicalTrials.gov registry entry for NCT05616013 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 507 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05616013 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05616013 about?
NCT05616013 is a clinical study titled "Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese". A phase 2 study to assess the efficacy of bimagrumab alone or in addition to semaglutide to assess efficacy and safety in overweight or obese men and women
What is the current status of trial NCT05616013?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 507 participants. The study started on 2022-11-16. Estimated completion is 2025-06-14.
What interventions are being tested in trial NCT05616013?
The interventions under investigation include: Placebo (OTHER), Semaglutide (DRUG), Bimagrumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05616013?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.